Guelph, Ont.The sign on the door of the plasma collection centre is cheerful. It reads, in the font of a rewards-card brochure, something about the gift of giving. The centre is clean. The chairs are comfortable, by the clinical standard of comfortable. The staff are, on every visit this magazine has made or documented, kind. The screens work: the health questions are thorough, the disqualifications are enforced, the process is safe by the standards the country's regulators have published and the facility meets. The donor lies back in the chair, the needle goes in, the machine separates the plasma from the whole blood and returns the red cells to the donor's vein, and forty-five minutes later the donor walks out with twenty-seven dollars on a prepaid card. The donor can come back in forty-eight hours. Twice a week, fifty-two weeks, the donor can collect somewhere in the neighbourhood of two hundred and eighty dollars a month. Before taxes, from which the country does not exempt plasma payments.

This magazine has, in the last two months, spoken with eleven regular plasma donors in this region. Nine of them are on Ontario Works. One is on Employment Insurance. One works part-time at a rate below the provincial living-wage benchmark. All eleven said the payment was material to their household budget. Seven of the eleven said they had altered other spending, or skipped a bill, or postponed a purchase, in weeks when their plasma screen failed and they did not receive payment. The plasma, in other words, is not a supplement. It is, for most of the people in the chairs, a budgeted income source. The country, when it licensed the for-profit plasma model, did not ask what it would mean to make the plasma of its poorest citizens a reliable income source. The country asked whether the process was safe. The process, by the relevant Health Canada standards, is safe. The question the country did not ask is a different kind of safe entirely.

What the plasma becomes

Plasma is not, in any of the forms in which the donor experiences it, a finished medicine. It is a raw material. Once collected, the plasma is shipped, in most cases, by refrigerated transport, to a fractionation facility. The fractionation facility processes the plasma into its component proteins: immunoglobulin, albumin, clotting factors, alpha-1 antitrypsin, and others. These are the finished medicines. They are used by people with primary immunodeficiency, by trauma patients, by surgical patients, by people with certain cancers and neurological conditions. They are not optional medicines. For many of the people who need them, they are the difference between function and incapacitation, and in the most serious cases, the difference between life and a preventable death.

The country needs these medicines. The country does not, on the current architecture of its voluntary-donation system, produce nearly enough plasma to manufacture them domestically. Canadian Blood Services, the non-profit that manages the country's voluntary whole-blood and stem-cell system, does not collect plasma for industrial fractionation. The organisation made this decision deliberately, in the 1990s, after the Krever inquiry into the tainted-blood crisis, when the country decided that a firewall between the voluntary system and the commercial plasma market was prudent. The firewall exists. The firewall means the country now imports, by the federal government's own published estimates, more than eighty per cent of its plasma-derived medicines from the United States, where the paid-donor model the country would prefer to call foreign has been running at scale for fifty years.

The country imports more than eighty per cent of its plasma-derived medicines from a system identical to the one it licenses here and looks politely away from.

The for-profit centres this country has licensed, in Guelph and Ottawa and Toronto and elsewhere, are filling a gap the country created by a policy decision the country then declined to follow through on. The country decided it would not collectplasma commercially. The country then became dependent on commercial plasma from a foreign country. The country then allowed foreign and domestic commercial operators to set up paid-collection centres on Canadian soil. The country is now, in every meaningful sense, running the paid-donor model it decided in the 1990s it would not run. It is running it out of sight, with a cheerful sign on the door, and the donors in the chairs are people who need the twenty-seven dollars.

The decision the country made about who would sit in the chairs

The decision was not written down anywhere. There was no policy paper, no ministerial directive, no parliamentary committee report that said: the people who will donate twice a week for a supplemental income will be people who need the supplemental income. This is the kind of outcome the country arrives at structurally, without a decision, by building an incentive structure and waiting for the incentive structure to sort the participants.

The incentive is twenty-seven dollars, twice a week, for forty-five minutes. For a citizen earning forty thousand dollars a year, this is not a meaningful incentive. For a citizen on Ontario Works, receiving seven hundred and thirty-three dollars a month, the standard single-person benefit rate as of this quarter, twenty-seven dollars is close to four per cent of the monthly income. For a donor who can sustain two sessions a week, which requires a body that passes the twice-weekly screen, the plasma payment adds roughly one hundred and fifty dollars to a seven-hundred-and-thirty-three-dollar monthly income. This is a twenty per cent income supplement. The country, which sets the OW rate and licenses the plasma centres, has not officially noted the relationship between these two numbers. The country has noticed that the centres are operating safely. The country has not asked who is operating them.

The country's only formal position on the question of paid plasma donation and the socioeconomic profile of donors is a 2022 expert panel report commissioned by the federal government, which noted that financial need can compromise the voluntariness of informed consent, recommended that the country monitor donor demographics, and was not, in any policy adoption that this magazine has been able to locate, acted on by any federal or provincial ministry. The report is available on a government website. The plasma centres are still open. The donors in the chairs are still overwhelmingly the people who need the twenty-seven dollars.

The medicine the country needs from people the country underpays

The country's publicly funded hospitals dispense immunoglobulin to patients on a clinical-need basis, under a nationally managed supply program. The supply program, in the last five years, has been subject to repeated allocation pressures and regional shortages. The shortages are the downstream consequence of the supply chain: Canada's plasma-derived medicine supply depends on the commercial plasma market, and the commercial plasma market depends, for its raw material, on people willing to sit in the chairs twice a week for twenty-seven dollars. When the number of people sitting in the chairs falls, as it does when collection centres close, when plasma payments are not competitive with other gig-economy options, when macroeconomic conditions change, the supply of medicine tightens. The patient on immunoglobulin at a Toronto hospital is, in a supply chain the hospital does not publicise and the country does not discuss, downstream from the person on Ontario Works in a plasma chair in Guelph.

The country has not, in any public-health communication this magazine has been able to locate, acknowledged this supply chain in plain language. The country has not, in any programme design this magazine has been able to locate, proposed an alternative. The country has not increased plasma payments to attract a broader donor demographic. The country has not built a voluntary plasma collection capacity inside the public system. The country has not increased OW rates to the point where the twenty-seven dollars from plasma is a genuine supplement rather than a structural necessity. The country has done none of these things. The country has licensed the centres, watched them fill with the people who need the payments, and published reports on the importance of a sustainable domestic plasma supply.

The verdict

Twenty-seven dollars. Forty-five minutes. Twice a week. The donor in the chair is not doing anything wrong. The staff at the centre are not doing anything wrong. The medicine that arrives at the hospital is real, and the patients who receive it are genuinely helped by it. None of this is wrong. The wrong is structural. The wrong is that the country that pays its poorest citizens for the contents of their veins, and imports the resulting medicine through a supply chain it declines to acknowledge in public, and calls this a health resource rather than a poverty premium, has confused extraction with healthcare.

The twenty-seven dollars, twice a week, is the country's cheapest price for the plasma its sickest citizens need. The country could pay a higher price. The country has chosen not to find out what a higher price would look like, because the current price fills the chairs, and the chairs fill the supply chain, and the supply chain fills the hospitals, and nobody in the chain has to say out loud what it is. This magazine is saying it out loud.